Merck Presents New Data of Keytruda (pembrolizumab) in Three Studies for the Treatment of Melanoma at SMR 2021
Shots: The new data from KEYNOTE-006/587/716 studies evaluate Keytruda in patients with melanoma. Patients were eligible for transition to KEYNOTE-587 for extended follow-up after KEYNOTE-006 […]